Thus, OEA-DS, modulating the activity of adiponectin, in combination with its expressed anti-inflammatory effect, may be particularly relevant in the complex therapy of MASLD, especially if this pathology is associated with such metabolic complications as obesity and hypercholesterolemia. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.